Showing 4891-4900 of 7029 results for "".
- Sun Pharma Acquires Ranbaxy in a $4 billion US Transactionhttps://practicaldermatology.com/news/20140407-sun_pharma_acquires_ranbaxy_in_a_4_billion_us__transaction/2459276/Sun Pharma will obtain 100% of Ranbaxy in an all stock transaction. The collaboration of these two pharmaceutical companies leads to the fifth largest generics company globally. There will be operations in 65 countries as well as 47 manufacturing facilities across 5 continents.
- Modernizing Medicine Named SIIA Software CODiE Award Finalist for Best Healthcare IT Solutionhttps://practicaldermatology.com/news/20140404-modernizing_medicine_named_siia_software_codie_award_finalist_for_best_healthcare_it_solution/2459278/
- Joseph R. Williams Becomes Vice President of Global Marketing for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140326-joseph_r_williams_becomes_vice_president_of_global_marketing_for_caliber_imaging__diagnostics/2459292/Caliber Imaging & Diagnostics named Joseph R. Williams Vice President of Global Marketing. Williams past experience led him to this new position. Previously, he was Director of Market Development at AxsunTechnologies/Volcano Corporation, Senior Director of Global Marketing-Neurosurgery Di
- Kerecis Receives US Patent for Fish-Skin-Based Tissue Regeneration Technologyhttps://practicaldermatology.com/news/20140219-kerecis_receives_us_patent_for_fish-skin-based_tissue_regeneration_technology/2459340/A US patent was awarded to Kerecis Limited for the use of fish skin in medical applications. The Kerecis material consists of sheets of intact, decellulariz
- Cosmetic Surgery Forum Offers Early-Bird Registrationhttps://practicaldermatology.com/news/20140204-cosmetic_surgery_forum_offers_early-bird_registration/2459349/
- Scioderm Initiates Phase IIB Study of SD-101 to Treat Epidermolysis Bullosahttps://practicaldermatology.com/news/20140107-scioderm_initiates_phase_iib_study_of_sd-101_to_treat_epidermolysis_bullosa/2459377/
- Mela Sciences Announces Realignment of Boardhttps://practicaldermatology.com/news/20140103-mela_sciences_announces_realignment_of_board/2459382/
- Provectus Announces Name Change to Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20131218-provectus_announces_name_change_to_provectus_biopharmaceuticals/2459391/
- Consumer Survey Reveals Widespread Problem of Excessive Sweating and Desire for New Topical Botulinum Toxin Treatmenthttps://practicaldermatology.com/news/20131118-consumer_survey_reveals_widespread_problem_of_excessive_sweating_and_desire_for_new_topical_botulinum_toxin_treatment/2459412/Anterios, Inc announced survey results about current consumer sentiment around exces
- Clinical Significance and Benefit from Scenesse in US Phase III EPP Studyhttps://practicaldermatology.com/news/20131113-clinical_significance_and_benefit_from_scenesse_in_us_phase_iii_epp_study/2459417/A Phase III study (CUV039) evaluating the administration of Scenesse (afamelanotide 16mg) to patients diagnosed with erythropoietic protoporphyria (EPP) has shown a clinically meaningful treatment effect, according to Clinuvel P